Overview Cardiac Safe Transplants for Systemic Sclerosis Status: Terminated Trial end date: 2019-10-09 Target enrollment: Participant gender: Summary This study is designed to treat systemic sclerosis (scleroderma) patients with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy that is less toxic to your heart. Phase: Phase 2/Phase 3 Details Lead Sponsor: Northwestern UniversityTreatments: Antilymphocyte SerumCyclophosphamideFludarabineFludarabine phosphateMethylprednisoloneMethylprednisolone AcetateMethylprednisolone HemisuccinatePrednisolonePrednisolone acetatePrednisolone hemisuccinatePrednisolone phosphateRituximabThymoglobulin